Metalloporphyrins as Therapeutic Catalytic Oxidoreductants in Central Nervous System Disorders
- 20 May 2014
- journal article
- review article
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 20 (15) , 2437-2464
Abstract
Significance: Metalloporphyrins, characterized by a redox-active transitional metal (Mn or Fe) coordinated to a cyclic porphyrin core ligand, mitigate oxidative/nitrosative stress in biological systems. Side-chain substitutions tune redox properties of metalloporphyrins to act as potent superoxide dismutase mimics, peroxynitrite decomposition catalysts, and redox regulators of transcription factor function. With oxidative/nitrosative stress central to pathogenesis of CNS injury, metalloporphyrins offer unique pharmacologic activity to improve the course of disease. Recent Advances: Metalloporphyrins are efficacious in models of amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, neuropathic pain, opioid tolerance, Parkinson's disease, spinal cord injury, and stroke and have proved to be useful tools in defining roles of superoxide, nitric oxide, and peroxynitrite in disease progression. The most substantive recent advance has been the synthesis of lipophilic metalloporphyrins offering improved blood–brain barrier penetration to allow intravenous, subcutaneous, or oral treatment. Critical Issues: Insufficient preclinical data have accumulated to enable clinical development of metalloporphyrins for any single indication. An improved definition of mechanisms of action will facilitate preclinical modeling to define and validate optimal dosing strategies to enable appropriate clinical trial design. Due to previous failures of “antioxidants” in clinical trials, with most having markedly less biologic activity and bioavailability than current-generation metalloporphyrins, a stigma against antioxidants has discouraged the development of metalloporphyrins as CNS therapeutics, despite the consistent definition of efficacy in a wide array of CNS disorders. Future Directions: Further definition of the metalloporphyrin mechanism of action, side-by-side comparison with “failed” antioxidants, and intense effort to optimize therapeutic dosing strategies are required to inform and encourage clinical trial design. Antioxid. Redox Signal. 20, 2437–2464.Keywords
This publication has 224 references indexed in Scilit:
- A new SOD mimic, Mn(III) ortho N-butoxyethylpyridylporphyrin, combines superb potency and lipophilicity with low toxicityFree Radical Biology and Medicine, 2012
- Manganese superoxide dismutase, MnSOD and its mimicsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- Manganese Porphyrin, MnTE-2-PyP5+, Acts as a Pro-Oxidant to Potentiate Glucocorticoid-Induced Apoptosis in Lymphoma CellsFree Radical Biology and Medicine, 2012
- Diverse functions of cationic Mn(III) N-substituted pyridylporphyrins, recognized as SOD mimicsFree Radical Biology and Medicine, 2011
- Measuring copper and zinc superoxide dismutase from spinal cord tissue using electrospray mass spectrometryAnalytical Biochemistry, 2011
- Mitochondrial dysfunction and oxidative stress: a contributing link to acquired epilepsy?Journal of Bioenergetics and Biomembranes, 2010
- Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activitiesAmino Acids, 2010
- Peroxynitrite and opiate antinociceptive tolerance: A painful realityArchives of Biochemistry and Biophysics, 2008
- Impact of electrostatics in redox modulation of oxidative stress by Mn porphyrins: Protection of SOD-deficient Escherichia coli via alternative mechanism where Mn porphyrin acts as a Mn carrierFree Radical Biology and Medicine, 2008
- A peroxynitrite decomposition catalyst counteracts sensory neuropathy in streptozotocin-diabetic miceEuropean Journal of Pharmacology, 2007